VERICEL CORPORATION Stock Split Ratio
VERICEL CORPORATION (VCEL) reported Stock Split Ratio of 5.00% for the 0-month period ending 2013-10-16, per its 10-K filed 2014-03-13.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2014-03-13
- 2013-10-16: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 5.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month |
|---|---|
| 2013-10-16 | 5.00% 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |